To include your compound in the COVID-19 Resource Center, submit it here.
AstraZeneca granted Leo exclusive, worldwide rights to tralokinumab ( CAT-354) for dermatological indications and exclusive, European rights to brodalumab ( KHK4827). For tralokinumab, AZ
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury